Description
This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4
Primary Industries
- Drugs
- Cancer
- Disease
- Therapeutic
- cell therapy
- Diagnostic
- Biotechnology
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 239908
License Grant
The Licensee received a worldwide, exclusive license to the Licensors rights in and to three patent families to develop and commercialize MultiTAA product candidates. These therapies are used as treatment for lymphoma, AML/MDS and multiple myeloma.
License Property
The MultiTAA T cell therapy platform is based on the adoptive T cell therapy technology that is licensed from the Licensor and that is presently available as a physician-sponsored investigational therapy for the treatment of lymphoma, AML/MDS and multiple myeloma.
Field of Use
The Licensee is a clinical-stage biopharmaceutical company currently developing MultiTAA T cell therapy technologies.
MultiTAA technology selectively expands non-engineered T cells, enhancing them with the ability to kill tumor cells by targeting multiple tumor-associated antigens simultaneously to prevent immune escape and generate durable immunity. Patient/donor T cells are not genetically modified and therefore the cost of generating Licensee's therapies is significantly reduced.
IPSCIO Record ID: 248290
License Grant
This amendment modifies the list of patents and adds sublicense clarifications. For clarity, sales of Licensed Products by Licensee or its Affiliate to a Sublicensee for resale by such Sublicensee are not included in Net Sales, sales of Licensed Products by a Sub licensee (including those Licensed Products purchased from Licensee or its Affiliates) to a Third Party that is not an Affiliate of such Sublicensee are included in Net Sales, and in the event that Licensee or an Affiliate of Licensee grants rights.
License Property
The amended list of patents include, but are not limited to Antitumor Vaccination Using Allogeneic Tumor Cells Expressing Alpha (1,3)-Galactosyltransferase; Method for Tumor Treatment Using Infusion of Xenogeneic Cells to Induce Hyperacute Rejection and Innocent Bystander Effect; Methods and Comp__ositions for Inducing Complement Destruction of Tissue; and, Herpes SimJ!lex Virus Amplicon Mini-Vector Gene Transfer System.
Field of Use
The patents are for cell therapies for tumor treatment.
IPSCIO Record ID: 3283
License Grant
The University hereby grants the Licensee an exclusive worldwide right and license in the Licensed field to practice under the Patent Rights and the Technology Rights and to make, have made, use, offer for sale, sell and import Licensed products or the practice of services utilizing the Licensed Processes. Licensee shall have an exclusive option to license any Invention. Licensee
shall have the right to grant sublicenses consistent with this Agreement.
License Property
United States Patent 7,668,659
Diagnosis and classification of multiple myeloma
United States Patent 7,308,364
Diagnosis of multiple myeloma on gene expression profiling
Field of Use
Licensed Field shall mean those applications of Patent Rights and/or the Technology Rights with respect to non-malignant and malignant human or animal pathologies, including but not limited to, determining and/or identifying the presence, predisposition, effect of treatment, mode or type of treatment, type of patient, susceptibility to treatment or prevention, progress of treatment, current and predicted clinical outcome, and/or therapeutic or prophylactic treatment and/or regimen.
IPSCIO Record ID: 307594
License Grant
The parties partnered to jointly develop and commercialize three of Licensor’s early-stage investigational bispecific antibody product candidates and enter into a discovery research collaboration for future differentiated antibody therapeutics for cancer.
License Property
Epcoritamab (DuoBody-CD3xCD20) is a bispecific antibody created using Licensor’s proprietary DuoBody technology. Epcoritamab is designed to target CD3, which is expressed on T cells and is part of the T cell receptor signaling complex, and CD20, a clinically well validated therapeutic target. CD20 is expressed on a majority of B cell malignancies, including chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), follicular lymphoma (FL) and mantle cell lymphoma (MCL). In a number of laboratory models, epcoritamab has shown highly effective killing of CD20+ tumors and induced potent tumor cell lysis across a panel of B cell tumor lines. Epcoritamab is currently evaluated in a Phase 1/2 study for multiple hematological B cell malignancies.
The companies will partner to develop Licensor’s next-generation bispecific antibody programs, epcoritamab (DuoBody®-CD3xCD20), DuoHexaBody®-CD37 and DuoBody-CD3x5T4. The collaboration combines Licensor’s world-class discovery and development engine and next-generation bispecific antibody therapeutic candidates with Licensee’s deep clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers. Licensor’s DuoBody-CD3 technology engages and directs cytotoxic T cells selectively to tumors to elicit an immune response towards malignant tumor cells. Licensee’s ADC technology allows the delivery of a therapeutic toxin directly to cancer cells while sparing normal, healthy cells, providing for a more targeted, less toxic treatment approach.
Licensor is a biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Licensors technology base consists of validated and proprietary next generation antibody technologies – the DuoBody® platform for generation of bispecific antibodies, the HexaBody® platform, which creates effector function enhanced antibodies, the HexElect® platform, which combines two co-dependently acting HexaBody molecules to introduce selectivity while maximizing therapeutic potency and the DuoHexaBody® platform, which enhances the potential potency of bispecific antibodies through hexamerization.
Field of Use
The field of use is for the treatment of cancer utilizing antibodies. Bispecific antibodies (also known as dual-targeting molecules) bind to two different epitopes, either on the same or on different targets. This may improve the antibodies’ specificity and efficacy in inactivating the disease target cells.
Licensee has a clinical expertise, innovative antibody-drug conjugate (ADC) platform and global commercial leadership in hematological cancers.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.
